Zymeworks Announces $200 Million Share Repurchase Authorization
Zymeworks Inc. has authorized a second 2026 share repurchase program, allowing for the buyback of up to $200 million of its common stock through 2028.
Stocks · News reference
Citizens has increased its price target for Zymeworks shares from $32.00 to $39.00.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Zymeworks Inc. has authorized a second 2026 share repurchase program, allowing for the buyback of up to $200 million of its common stock through 2028.
Filed: 2026-11-16 AccNo: 0001937653-26-000070 Size: 197 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Zymeworks announced its financial results for the third quarter of 2026, reporting revenue of $256.5 million and earnings per share of $2.28, while raising its full-year 2026 financial guidance.